Adverum Biotechnologies, Inc.: net property, plant and equipment
Net property, plant and equipment for Adverum Biotechnologies, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Adverum Biotechnologies, Inc. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-12-31 to 2024-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2024-12-31 | 11,607,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2024-09-30 | 12,215,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2024-06-30 | 13,047,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2024-03-31 | 13,766,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2023-12-31 | 14,764,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2023-09-30 | 15,497,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2023-06-30 | 32,041,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2023-03-31 | 33,347,000 | USD | 2025-04-15 | 10-K · 0001628280-25-017767 |
| At date | 2022-12-31 | 34,927,000 | USD | 2024-03-18 | 10-K · 0001628280-24-011648 |
| At date | 2021-12-31 | 33,060,000 | USD | 2023-03-30 | 10-K · 0001628280-23-009899 |
| At date | 2020-12-31 | 27,725,000 | USD | 2022-03-29 | 10-K · 0001628280-22-007698 |
| At date | 2019-12-31 | 24,884,000 | USD | 2021-03-01 | 10-K · 0001628280-21-003623 |
| At date | 2018-12-31 | 3,586,000 | USD | 2020-03-12 | 10-K · 0001564590-20-010503 |
| At date | 2017-12-31 | 3,024,000 | USD | 2019-03-06 | 10-K · 0001564590-19-006536 |
| At date | 2016-12-31 | 4,169,000 | USD | 2018-03-06 | 10-K · 0001564590-18-004560 |
| At date | 2015-12-31 | 3,187,000 | USD | 2017-03-09 | 10-K · 0001564590-17-003759 |
| At date | 2014-12-31 | 1,085,000 | USD | 2016-03-04 | 10-K · 0001564590-16-014022 |
| At date | 2013-12-31 | 69,000 | USD | 2015-03-05 | 10-K · 0001193125-15-078923 |
Related financial histories
- Adverum Biotechnologies, Inc.: total assets
- Adverum Biotechnologies, Inc.: total liabilities
- Adverum Biotechnologies, Inc.: stockholders equity
- Adverum Biotechnologies, Inc.: cash and cash equivalents
- Adverum Biotechnologies, Inc.: net income or loss
- Adverum Biotechnologies, Inc.: operating cash flow
- Adverum Biotechnologies, Inc.: capital expenditure payments
- Adverum Biotechnologies, Inc.: revenue
- Adverum Biotechnologies, Inc.: contract revenue excluding tax
- Adverum Biotechnologies, Inc.: financing cash flow
- Adverum Biotechnologies, Inc.: investing cash flow
- Adverum Biotechnologies, Inc.: retained earnings or deficit
- Adverum Biotechnologies, Inc.: basic weighted-average shares
- Adverum Biotechnologies, Inc.: diluted weighted-average shares
- Adverum Biotechnologies, Inc.: basic earnings per share
- Adverum Biotechnologies, Inc.: diluted earnings per share
- Adverum Biotechnologies, Inc.: income tax expense or benefit
- Adverum Biotechnologies, Inc.: share-based compensation expense
- Adverum Biotechnologies, Inc.: operating income or loss
- Adverum Biotechnologies, Inc.: current assets
- Adverum Biotechnologies, Inc.: interest expense
- Adverum Biotechnologies, Inc.: current liabilities
- Adverum Biotechnologies, Inc.: current accounts payable
- Adverum Biotechnologies, Inc.: operating expenses
- Adverum Biotechnologies, Inc.: research and development expense
- Adverum Biotechnologies, Inc.: common shares outstanding
- Adverum Biotechnologies, Inc.: cash including restricted cash
- Adverum Biotechnologies, Inc.: accumulated other comprehensive income or loss
- Adverum Biotechnologies, Inc.: operating lease right-of-use asset
- Adverum Biotechnologies, Inc.: operating lease liability
- Adverum Biotechnologies, Inc.: gross property, plant and equipment
- Adverum Biotechnologies, Inc.: accumulated depreciation on property, plant and equipment
- Adverum Biotechnologies, Inc.: other noncurrent assets
- Adverum Biotechnologies, Inc.: other noncurrent liabilities
- Adverum Biotechnologies, Inc.: prepaid expenses and other current assets
- Adverum Biotechnologies, Inc.: net deferred tax assets
- Adverum Biotechnologies, Inc.: pre-tax income or loss from continuing operations
- Adverum Biotechnologies, Inc.: profit or loss including noncontrolling interests
- Adverum Biotechnologies, Inc.: comprehensive income or loss
- Adverum Biotechnologies, Inc.: net income available to common stockholders
- Adverum Biotechnologies, Inc.: general and administrative expense
- Adverum Biotechnologies, Inc.: depreciation expense
- Adverum Biotechnologies, Inc.: other nonoperating income or expense
- Adverum Biotechnologies, Inc.: nonoperating income or expense
- Adverum Biotechnologies, Inc.: current income tax expense or benefit
- Adverum Biotechnologies, Inc.: deferred income tax expense or benefit
- Adverum Biotechnologies, Inc.: proceeds from issuing common stock
- Adverum Biotechnologies, Inc.: operating lease payments
- Adverum Biotechnologies, Inc.: change in accounts receivable
- Adverum Biotechnologies, Inc.: change in accounts payable
Inspect the source
- Entity
- Adverum Biotechnologies, Inc. / CIK 0001501756
- Captured
- 2026-09-21T17:19:30.277Z
- SEC response SHA-256
3e3f88b341f4a0ffa9ee013477a8ae8ec2c292f96270a497f1b280e9a59501b4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001501756.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))